Therapeutic angiogenesis for peripheral artery diseases by combination of adrenomedullin and peripheral mononuclear cell transplantation

Therapeutic angiogenesis for peripheral artery diseases by combination of adrenomedullin and peripheral mononuclear cell transplantation - Therapeutic angiogenseis by combination of adrenomedullin and cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000199

Enrollment

Registered

2005-09-13

Start date

2004-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral artery disease

Interventions

Transplantation of peripheral mononuclear cells into ischemic limb muscles, followed by administration of adrenomedullin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with rest pain, non-healing ischemic ulcers, and/or intermittent claudication. 2)Significant stenosis in superficial femoral, popliteal, and/or below knee arteries by DSA, CTA, and/or MRA. 3)Patients who are not candidates for angioplasty or bypass surgery. 4)Written informed consent.

Exclusion criteria

Exclusion criteria: 1)malignant disorder. 2)uncontrolled liver disorder. 3)acute myocardial infarction, unstable angina, myocarditis, cerebral infarction within one month. 4)active infection. 5)pregnancy or child bearing potentials. 6)diabetic retinopathy (untreated proliferative retinopathy).

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
Improvement of pain, skin necrosis, and walking distance	—

Countries

Japan

Contacts

Public ContactSatoshi Takeshita

National Cardiovascular Center Cardiology

06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026